Companies › Huabo Biopharm
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Immunology, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HB0017 Injection | – | Phase 2 | Psoriasis (PsO); Psoriasis | Dec 2026 |
| HB0025 | – | Phase 1 | Advanced NSCLC | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06592274 | HB0017 Injection | Phase 2 | Psoriasis (PsO) | Immunology | Apr 2025 |
| NCT06758557 | HB0025 | Phase 1 | Advanced NSCLC | Oncology | Oct 2025 |
| NCT07920861 | HB0017 Injection | Phase 1 | Psoriasis | Immunology | Dec 2026 |
No annotated target.
–
Telios Pharma Molecure Tavotek Biotherapeutics Xizang Haisco Pharmaceutical Antengene Biologics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.